Skip to search formSkip to main contentSkip to account menu

ZD 9331

Known as: BGC 9331, ZD9331, ZD-9331 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Antineoplastic AgentsQuinazolines
Plevitrexedtopotecan/ZD9331

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Structural determinants for the intracellular degradation of human thymidylate synthase.
Thymidylate synthase (EC 2.1.1.45) (TS) catalyzes the conversion of dUMP to dTMP and is therefore indispensable for DNA… 
2004
2004
P21Cip1 Is a Critical Mediator of the Cytotoxic Action of Thymidylate Synthase Inhibitors in Colorectal Carcinoma Cells
We have demonstrated previously that interferon (IFN)-γ sensitizes human colon carcinoma cell lines to the cytotoxic effects of 5… 
2003
2003
A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
PURPOSE ZD9331 is a novel, direct-acting antifolate cytotoxic that does not require polyglutamation for activity, and is a… 
2003
2003
Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
PURPOSE This dose-escalating study investigated the toxicity, pharmacokinetics, and efficacy of the novel direct-acting… 
Review
2003
Review
2003
A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours
Background Non‐small cell lung cancer (NSCLC), ovarian and breast cancers, especially in advanced stages, are difficult to treat… 
Highly Cited
2002
Highly Cited
2002
Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
2002
2002
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS…
5-Fluorouracil (5-FU) exerts cytotoxic effects through inhibition of thymidylate synthase (TS) and incorporation of metabolites… 
Review
1996
Review
1996
Section Review: Oncologic, Endocrine & Metabolic: The new generation of thymidylate synthase inhibitors in clinical study
In the last five years, six new antifolate drugs, all targeted towards thymidylate synthase (TS), have entered clinical studies… 
Review
1995
Review
1995
Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.
Carboplatin is a better-tolerated alternative to cisplatin. JM216, the first p.o.-administrable platinum complex possesses… 
Review
1994
Review
1994
The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor.
Thymidylate synthase (TS) is regarded as a good target for the development of quinazoline (folate-based) anticancer agents. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)